Pivotal Data Validates Diagnostic Equivalence of SCANLY Home OCT and In-Office OCT in Wet AMD Management
Until now, the ability of wet AMD patients to self-image on a compact, home-based OCT device had only been demonstrated in smaller longitudinal at-home 2,3 and cross-sectional in-office studies. 4 This pivotal longitudinal study expanded on those findings and demonstrated strong agreement between SCANLY-acquired images and standard in-office OCT in identifying hypo-reflective spaces (HRS), an important biomarker in wet AMD that typically indicates fluid. Conducted across seven U.S. retina practices representing a mix of urban and rural populations, the longitudinal trial enrolled 180 patients from a broader 500-subject study program, including those with concurrent ocular conditions to reflect real-world pathology.
Participants received SCANLY devices via courier from the Notal Vision Monitoring Center. They did not receive any training on how to use the device but had the option to call the Monitoring Center for support if needed. Patients were instructed to self-image daily over a five-week period. To assess image agreement, patients also underwent 2-3 in-office visits for comparative OCT scans. All images were independently graded by masked graders for the presence of HRS.
SCANLY met its prespecified endpoint of ≥80% agreement, achieving a positive percent agreement (PPA) of 86.6% and a negative percent agreement (NPA) of 86.1%. Discrepancies were primarily attributed to grader errors or trace amounts of HRS.
The study also confirmed high patient usability: 96.1% of eligible participants successfully initiated at-home imaging, averaging 5.9 scans per eye per week. Phone support was minimally required, with patients averaging just 0.21 support calls per month.
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/10516/257551_9a80f8cc647a890c_001.jpg ]
Figure: Side-by-side comparison of SCANLY and in-office OCT demonstrating high concordance in detecting hypo-reflective spaces in wet AMD patients.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10516/257551_9a80f8cc647a890c_001full.jpg
'Home-based OCT monitoring represents a fundamental shift in personalized retina care,' said Jeffrey S. Heier, MD, Director of the Retina Service at Ophthalmic Consultants of Boston. 'The SCANLY pivotal data and subsequent FDA clearance represents a significant advance in remote diagnostics for chronic retinal disease.'
'We're proud to share these robust findings,' added Kester Nahen, PhD, CEO of Notal Vision. 'They validate that patients with wet AMD can reliably self-image at home, supporting treating retina specialists in their clinical decision-making between office visits.'
The SCANLY Home OCT Monitoring Program, provided by the Notal Vision Monitoring Center, enables prescribing retina specialists to leverage AI-enabled alerts and real-time imaging data to individualize care while maintaining clinical oversight.
References:
1. Heier, Jeffrey S., et al. Pivotal Trial Validating Usability and Visualization Performance of Home OCT in Neovascular Age-Related Macular Degeneration: Report 1. Ophthalmol Sci. 2025 Mar 21;5(5):100772. doi: 10.1016/j.xops.2025.100772.
2. Blinder, Kevin J., et al. Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study. Ophthalmol Retina. 2023 Oct 23:S2468-6530(23)00514-6. doi: 10.1016/j.oret.2023.10.012
3. Liu, Yingna, Nancy M. Holekamp, and Jeffrey S. Heier. Prospective, longitudinal study: daily self-imaging with home OCT for neovascular age-related macular degeneration. Ophthalmology Retina. 2022 Jul;6(7):575-585. doi: 10.1016/j.oret.2022.02.011
4. Kim, Judy E., et al. Evaluation of a self-imaging SD-OCT system designed for remote home monitoring. BMC Ophthalmol. 22, 261 (2022). doi: 10.1186/s12886-022-02458-z
###
About Notal Vision
Notal Vision is a patient-centric ophthalmic remote monitoring services provider extending care from the clinic to the home. We empower physicians with innovative home-based technologies and remote monitoring services that support patient management between office visits. Our solutions combine self-operated digital diagnostic devices, AI-enabled data analysis, and a physician-led monitoring center-all with the goal of helping preserve patients' vision. Learn more at www.notalvision.com
The Medicare-accredited and ophthalmologist-led Notal Vision Monitoring Center is dedicated to remote monitoring and patient engagement. Staffed by certified ophthalmic professionals, the center provides nationwide service for age-related macular degeneration (AMD) monitoring.
Notal Vision offers two distinct remote monitoring solutions:
Together, these programs support physicians across the full spectrum of AMD care-from early detection to ongoing disease management.
Media Contact:
Candice Morin
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257551
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
2 minutes ago
- Los Angeles Times
U.S. will get a 15% cut of Nvidia and AMD chip sales to China under a new, unusual agreement
NEW YORK — Nvidia and AMD have agreed to share 15% of their revenues from chip sales to China with the U.S. government, as part of a deal to secure export licenses for the semiconductors. The Trump administration halted the sale of advanced computer chips to China in April over national security concerns, but Nvidia and AMD revealed in July that Washington would allow them to resume sales of the H20 and MI308 chips, which are used in artificial intelligence development. President Trump confirmed the terms of the unusual arrangement in a Monday press conference while noting that he originally wanted 20% of the sales revenue when Nvidia asked to sell the 'obsolete' H20 chip to China. The president credited Nvidia CEO Jensen Huang for negotiating him down to 15%. 'So we negotiated a little deal. So he's selling a essentially old chip,' Trump said. Nvidia did not comment about the specific details of the agreement or its quid pro quo nature, but said they would adhere to the export rules laid out by the administration. 'We follow rules the U.S. government sets for our participation in worldwide markets. While we haven't shipped H20 to China for months, we hope export control rules will let America compete in China and worldwide,' Nvidia wrote in a statement to the AP. 'America cannot repeat 5G and lose telecommunication leadership. America's AI tech stack can be the world's standard if we race.' AMD did not immediately reply to a request for comment. The top Democrat on a House panel focusing on competition with China raised concerns over the reported agreement, calling it 'a dangerous misuse of export controls that undermines our national security.' Rep. Raja Krishnamoorthi, the ranking member of the House Select Committee on China, said he would seek answers about the legal basis for this arrangement and demand full transparency from the administration. 'Our export control regime must be based on genuine security considerations, not creative taxation schemes disguised as national security policy,' he said. 'Chip export controls aren't bargaining chips, and they're not casino chips either. We shouldn't be gambling with our national security to raise revenue.' Derek Scissors, senior fellow and China expert at the conservative American Enterprise Institute, questioned the constitutionality of the deal and also warned against risking national security for revenue. 'There's no precedent for this, probably because export taxes are unconstitutional, ' said Derek Scissors, senior fellow and China expert at the conservative American Enterprise Institute. 'They call it a fee, but 15% of sales revenue is about a standard a tax as it comes. For this reason, I don't think the 'arrangement' is at all durable. '' 'If it were to last, it has two possible implications. First, there's a possible export tax that high-profile companies and goods must consider. Or the tax only applies in exceptional situations, such as changing export controls. Then we'd risk national security for the sake of tax revenue, which is effectively the same as cutting the defense budget,' Scissors said. Back in July, Nvidia argued that tight export controls around their chip sales would cost the company an extra $5.5 billion. They've argued that such limits hinder U.S. competition in a sector in one of the world's largest markets for technology, and have also warned that U.S. export controls could end up pushing other countries toward China's AI technology. Commerce Secretary Howard Lutnick told CNBC in July that the renewed sale of Nvidia's chips in China was linked to a trade agreement made between the two countries on rare earth magnets. Restrictions on sales of advanced chips to China have been central to the AI race between the world's two largest economic powers, but such controls are also controversial. Proponents argue that these restrictions are necessary to slow China down enough to allow U.S. companies to keep their lead. Meanwhile, opponents say the export controls have loopholes — and could still spur innovation. The emergence of China's DeepSeek AI chatbot in January particularly renewed concerns over how China might use advanced chips to help develop its own AI capabilities. Associated Press writers Josh Boak, Shawn Chen, Didi Tang and Paul Wiseman contributed to the reporting.
Gizmodo
2 minutes ago
- Gizmodo
Handsoaps Recalled Over Bacteria That Can Cause Sepsis
Four brands of soap and skin products are being recalled by their manufacturer after they were discovered to potentially be contaminated with bacteria that can cause infections, and even lead to sepsis in immunosuppressed people, according to announcements from the FDA and DermaRite Industries. The products, DermaKleen, KleenFoam, DermaSarra, and PeriGiene, have been recalled nationwide in the U.S. and Puerto Rico over the bacteria Burkholderia cepacia (spelled as cepecia in the FDA press release), though the health agency didn't indicate how the contamination of the soaps may have occurred. The announcements from the FDA and DermaRite Industries also didn't state where the soaps and skin products were sold, though listings online suggest the soaps are often purchased by companies and institutions for use in public facilities. It's not clear how popular the products may be at physical retail stores where the average consumer might buy them for use in the home, though they are available at online retailers like Amazon. Neither DermaRite nor the FDA immediately responded to questions Monday. The FDA's description of the recalled products: 'In healthy individuals with minor skin lesions the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis,' the company said in a statement posted online. 'To date, DermaRite has not received any reports of adverse events related to this recall.' Consumers who believe they're experiencing issues after using these products are encouraged to contact their doctors. The lot numbers and expiration dates for the recalled products, according to DermaRite: Consumers who have questions about the recall are encouraged to call Mary Goldberg at DermaRite Industries at the number 973-569-9000 x104, Monday through Friday, from 9:00 am to 5:00 pm ET, according to the company's press release. The company can also be reached by email at: [email protected].
Medscape
2 minutes ago
- Medscape
FDA Okays Ketamine-Based Med for Post-Surgical Pain
The FDA has approved the racemic ketamine product known as KETARx (PharmaTher Holdings) for the treatment of post-surgical pain. 'This historic FDA approval…is a testament to years of dedicated development,' Fabio Chianelli, chairman and CEO of PharmaTher, said in a release. 'We remain steadfast in our mission to harness the pharmaceutical potential of ketamine for a range of mental health, neurological, and pain disorders,' he added. The company noted that it hopes to expand ketamine development into conditions such as Parkinson's disease, amyotrophic lateral sclerosis, depression, and complex regional pain syndrome. Its product has already received an orphan drug designation for the treatment of Rett syndrome. It added that, among psychedelic and 'psychedelic-adjacent' drugs, ketamine is the only one to be included on a list of Essential Medicines by the World Health Organization. The company initially announced that the FDA had set an approval goal date of April 2024 for KETARx. However, after 'minor deficiencies identified by Quality' were identified, the FDA assigned a new target date of October 2024. As reported by Medscape Medical News at the time, the FDA issued a complete response letter requesting additional information on the application. The final date of August 2025 was set after the company submitted the requested additional information.
